For the treatment of various types of schizophrenia. Foreign clinical trials have shown that this product has obvious curative effect on both positive and negative symptoms of schizophrenia, and can also improve the accompanying emotional symptoms and reduce the recurrence rate of schizophrenia.

Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia.
Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin
Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower
potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of
Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.